China Resources Double-Crane Pharmaceutical's Subsidiary Zhongshuai Pharma Passes Drug GMP Compliance Inspection

Stock News11-02

China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) has announced that its controlled subsidiary, Henan Zhongshuai Pharmaceutical Technology Co., Ltd. (referred to as "Zhongshuai Pharma"), recently received a Drug GMP Compliance Inspection Notification Letter issued by the Henan Provincial Medical Products Administration.

The product involved is Acetazolamide Sustained-Release Capsules (specification: 0.5g, National Drug Approval Number H20265455). The solid preparation workshop and the capsule production line passed this drug GMP compliance inspection.

Acetazolamide Sustained-Release Capsules are the first drug approved in China for the prevention or improvement of acute mountain sickness. It was approved for market launch in August 2026 and has not yet generated market sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment